ASTRAZENECA PLC ANNOUNCES ZURAMPIC (LESINURAD) APPROVED IN THE EUROPEAN UNION FOR PATIENTS WITH GOUT

AstraZeneca today announced that the European Commission (EC) has granted
marketing authorisation for ZurampicTM(lesinurad) 200mg in combination with a
xanthine oxidase inhibitor (XOI) for the adjunctive treatment of hyperuricemia
in adult gout patients (with or without tophi) who have not achieved target
serum uric acid (sUA) levels with an adequate dose of an XOI alone.

Click on, or paste the following link into your web browser, to view the
associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/5248P_1-2016-2-18.pdf